Maze Therapeutics (NASDAQ:MAZE) Stock Price Up 4.5% – Here’s Why

Posted by Brenda Bartman on Sep 28th, 2026

Maze Therapeutics, Inc. (NASDAQ:MAZE – Get Free Report) shares shot up 4.5% during mid-day trading on Monday. The company traded as high as $26.91 and last traded at $27.2110. 354,721 shares were traded during mid-day trading, a decline of 46% from the average daily volume of 662,192 shares. The stock had previously closed at $26.05.

Wall Street Analysts Forecast Growth

A number of analysts have commented on MAZE shares. Wall Street Zen downgraded shares of Maze Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. HC Wainwright reiterated a “buy” rating and issued a $110.00 price objective on shares of Maze Therapeutics in a report on Thursday. Citigroup started coverage on shares of Maze Therapeutics in a research note on Wednesday, September 23rd. They set a “buy” rating and a $50.00 price objective on the stock. BTIG Research restated a “buy” rating and issued a $46.00 target price on shares of Maze Therapeutics in a research report on Tuesday, September 22nd. Finally, Wedbush reaffirmed an “outperform” rating and set a $48.00 price target on shares of Maze Therapeutics in a research note on Wednesday, September 23rd. Three investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Maze Therapeutics has a consensus rating of “Buy” and an average price target of $63.40.

Check Out Our Latest Stock Analysis on MAZE

Maze Therapeutics Price Performance

The company has a debt-to-equity ratio of 0.09, a quick ratio of 18.31 and a current ratio of 18.31. The company’s 50 day moving average price is $27.12 and its 200-day moving average price is $28.91. The company has a market cap of $1.50 billion, a price-to-earnings ratio of -10.68 and a beta of 2.17.

Maze Therapeutics (NASDAQ:MAZE – Get Free Report) last released its earnings results on Tuesday, August 11th. The company reported ($0.76) EPS for the quarter, meeting the consensus estimate of ($0.76). On average, equities research analysts forecast that Maze Therapeutics, Inc. will post -2.72 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CMO Harold Bernstein sold 9,705 shares of the company’s stock in a transaction on Friday, September 4th. The stock was sold at an average price of $26.22, for a total transaction of $254,465.10. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Courtney Phillips sold 2,012 shares of the stock in a transaction on Thursday, September 3rd. The shares were sold at an average price of $26.01, for a total value of $52,332.12. Following the completion of the transaction, the insider owned 7,007 shares of the company’s stock, valued at $182,252.07. This trade represents a 22.31% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders sold 183,959 shares of company stock valued at $5,053,389. 5.30% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in MAZE. TRV GP IV LLC purchased a new stake in shares of Maze Therapeutics in the 2nd quarter valued at approximately $133,502,907. ARCH Venture Management LLC purchased a new position in Maze Therapeutics during the 2nd quarter worth approximately $122,983,582. BlackRock Inc. purchased a new position in Maze Therapeutics during the 2nd quarter worth approximately $104,525,000. Jupiter Topco LLC acquired a new stake in Maze Therapeutics during the 2nd quarter valued at $101,764,000. Finally, Alphabet Inc. acquired a new stake in Maze Therapeutics during the 2nd quarter valued at $41,435,000.

About Maze Therapeutics

(Get Free Report)

Maze Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetically driven diseases. The company combines human genetics, functional genomics and drug discovery technologies through its Maze Compass platform to identify disease mechanisms and develop therapies designed to address the underlying causes of disease.

Maze’s lead program, MZE001, is an oral small-molecule inhibitor of glycogen synthase being developed for Pompe disease, a rare inherited disorder in which glycogen accumulates in muscles and other tissues.